Bepridil

a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties

Joseph S Alpert, P. Coumel, K. Greeff, D. M. Krikler, W. J. Remme, E. Schönbaum, C. W. Verduyn

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Bepridil is an anti-anginal agent with a novel chemical structure. Its main pharmacological effects are an increase in coronary blood flow, a reduction in myocardial oxygen demand, reduction in cardiac work, primarily by a decrease in after-load and a dose-dependent negative chronotropic effect, and anti-arrhythmic properties. These are mainly due to a calcium-antagonistic action. There is evidence that fast sodium channels in heart muscle are also inhibited. Trials have shown that bepridil is effective in the prophylactic treatment of various forms of angina pectoris and accompanying arrhythmias. Pharmacokinetic data justify once-daily administration. The evidence suggests that bepridil is generally well tolerated. This paper reviews already published studies and the results of recent investigations on the pharmacological and clinical efficacy of bepridil.

Original languageEnglish (US)
Pages (from-to)195-222
Number of pages28
JournalPharmatherapeutica
Volume4
Issue number4
StatePublished - 1985
Externally publishedYes

Fingerprint

Bepridil
Anti-Arrhythmia Agents
Pharmacology
Sodium Channels
Angina Pectoris
Cardiac Arrhythmias
Myocardium
Pharmacokinetics
Oxygen
Calcium

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Alpert, J. S., Coumel, P., Greeff, K., Krikler, D. M., Remme, W. J., Schönbaum, E., & Verduyn, C. W. (1985). Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties. Pharmatherapeutica, 4(4), 195-222.

Bepridil : a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties. / Alpert, Joseph S; Coumel, P.; Greeff, K.; Krikler, D. M.; Remme, W. J.; Schönbaum, E.; Verduyn, C. W.

In: Pharmatherapeutica, Vol. 4, No. 4, 1985, p. 195-222.

Research output: Contribution to journalArticle

Alpert, JS, Coumel, P, Greeff, K, Krikler, DM, Remme, WJ, Schönbaum, E & Verduyn, CW 1985, 'Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties', Pharmatherapeutica, vol. 4, no. 4, pp. 195-222.
Alpert, Joseph S ; Coumel, P. ; Greeff, K. ; Krikler, D. M. ; Remme, W. J. ; Schönbaum, E. ; Verduyn, C. W. / Bepridil : a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties. In: Pharmatherapeutica. 1985 ; Vol. 4, No. 4. pp. 195-222.
@article{531ee6a388f14fb69dea33bf5e462ced,
title = "Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties",
abstract = "Bepridil is an anti-anginal agent with a novel chemical structure. Its main pharmacological effects are an increase in coronary blood flow, a reduction in myocardial oxygen demand, reduction in cardiac work, primarily by a decrease in after-load and a dose-dependent negative chronotropic effect, and anti-arrhythmic properties. These are mainly due to a calcium-antagonistic action. There is evidence that fast sodium channels in heart muscle are also inhibited. Trials have shown that bepridil is effective in the prophylactic treatment of various forms of angina pectoris and accompanying arrhythmias. Pharmacokinetic data justify once-daily administration. The evidence suggests that bepridil is generally well tolerated. This paper reviews already published studies and the results of recent investigations on the pharmacological and clinical efficacy of bepridil.",
author = "Alpert, {Joseph S} and P. Coumel and K. Greeff and Krikler, {D. M.} and Remme, {W. J.} and E. Sch{\"o}nbaum and Verduyn, {C. W.}",
year = "1985",
language = "English (US)",
volume = "4",
pages = "195--222",
journal = "Pharmatherapeutica",
issn = "0308-051X",
number = "4",

}

TY - JOUR

T1 - Bepridil

T2 - a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties

AU - Alpert, Joseph S

AU - Coumel, P.

AU - Greeff, K.

AU - Krikler, D. M.

AU - Remme, W. J.

AU - Schönbaum, E.

AU - Verduyn, C. W.

PY - 1985

Y1 - 1985

N2 - Bepridil is an anti-anginal agent with a novel chemical structure. Its main pharmacological effects are an increase in coronary blood flow, a reduction in myocardial oxygen demand, reduction in cardiac work, primarily by a decrease in after-load and a dose-dependent negative chronotropic effect, and anti-arrhythmic properties. These are mainly due to a calcium-antagonistic action. There is evidence that fast sodium channels in heart muscle are also inhibited. Trials have shown that bepridil is effective in the prophylactic treatment of various forms of angina pectoris and accompanying arrhythmias. Pharmacokinetic data justify once-daily administration. The evidence suggests that bepridil is generally well tolerated. This paper reviews already published studies and the results of recent investigations on the pharmacological and clinical efficacy of bepridil.

AB - Bepridil is an anti-anginal agent with a novel chemical structure. Its main pharmacological effects are an increase in coronary blood flow, a reduction in myocardial oxygen demand, reduction in cardiac work, primarily by a decrease in after-load and a dose-dependent negative chronotropic effect, and anti-arrhythmic properties. These are mainly due to a calcium-antagonistic action. There is evidence that fast sodium channels in heart muscle are also inhibited. Trials have shown that bepridil is effective in the prophylactic treatment of various forms of angina pectoris and accompanying arrhythmias. Pharmacokinetic data justify once-daily administration. The evidence suggests that bepridil is generally well tolerated. This paper reviews already published studies and the results of recent investigations on the pharmacological and clinical efficacy of bepridil.

UR - http://www.scopus.com/inward/record.url?scp=0021821025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021821025&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 195

EP - 222

JO - Pharmatherapeutica

JF - Pharmatherapeutica

SN - 0308-051X

IS - 4

ER -